“Matching” the “Mismatch” Repair–Deficient Prostate Cancer with Immunotherapy
Abstract
Mismatch repair gene mutations are uncommon in advanced prostate cancer; however, in those harboring these alterations, immune checkpoint blockade can be effective. As such, assays that can accurately identify these men are critically important. Cell-free circulating tumor DNA–based sequencing approaches appear to be one viable approach for identifying these patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3780
Entities
People
- Evan Y. Yu
- Michael T Schweizer
Organizations
- Fred Hutchinson Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- University of Washington